Search

Osteoporosis (OP) is a chronic disease that affects older adults' quality of life, with fragility fractures (FF) being its most significant consequence due to their impact on healthcare systems in terms of morbidity, and economic and caregiving burden. FF are defined as fractures resulting from low-energy trauma, defined as falls from a standing height or less, and are usually considered osteoporotic (1). World demographic projections warn of a significant increase in adults aged 65 and older by 2050. These demographic changes mean that OP and FF will soon become an even greater challenge for healthcare systems, where prevention programs should be a priority. In Mexico, FF is also a public health challenge, with an initial reported incidence of nearly 2,000 cases per 100,000 population, and a projected seven-fold increase by 2050. Given this scenario, there is an urgent need for policy- and decision-makers to change their approach and formulate health policies that guarantee that people aged 65 and older are screened for fractures and have access to appropriate care. These policies should be part of a strategy to minimize FF and ensure active and healthy aging according to the WHO's Decade of Healthy Ageing. In this context, a group of Mexican experts representing different health organizations interested in the burden of OP and FF met to discuss possible strategies to reduce their burden for the next decade and summarize them in this Call to Action to promote public policies that prioritize an evidence-based approach to the prevention and treatment of OP and FF. [ABSTRACT FROM AUTHOR]

Background: Controversy exists regarding the optimal dose of radioiodine (131I) therapy in autoimmune hyperthyroidism (i.e., Graves'' Disease). Methods: In order to evaluate the efficacy and safety of high dose 131I therapy in autoimmune hyperthyroidism, a retrospective review of patients who received 131I therapy for Graves'' disease from 1980 to 2000 in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City was carried out. Results: The study population consisted of 596 autoimmune hyperthyroid patients with a mean age of 35 years. The mean follow-up period was 10.31 ± 2.37 years. Remission of hyperthyroidism occurred in 81.9%, persistent hyperthyroidism was recorded in 14.4% and recurrence in 3.7%. 131I doses of 5–9 mCi (185–333 MBq) and ≥20 mCi (≥740 MBq) were associated with remission rates of 65.5% and 87.7% respectively. Remission occurred earlier and more often with high doses of 131I. The high-dose group (20–30 mCi [740–1110 MBq]) had the lowest rate of persistence (9.7, 27.5 and 34.3%, for 20–30 [740–1110 MBq], 10–14 [370–518 MBq] and 5–9 [185–333 MBq] mCi, respectively p <0.05) and hypothyroidism occurred earlier in this group (p = 0.05). Conclusions: Remission of autoimmune hyperthyroidism is more likely with doses of 20–30 mCi (740–1110 MBq). [Copyright &y& Elsevier]